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SUMMARY
The phosphoinositide phosphatase synaptojanin 1 (SYNJ1) is a key regulator of synaptic function. 
We first tested whether SYNJ1 contributes to phenotypic variations in familial Alzheimer’s 
disease (FAD) and show that SYNJ1 polymorphisms are associated with age of onset in both 
early- and late-onset human FAD cohorts. We then interrogated whether SYNJ1 levels could 
directly affect memory. We show that increased SYNJ1 levels in autopsy brains from adults with 
Down syndrome (DS/AD) are inversely correlated with synaptophysin levels, a direct readout of 
synaptic integrity. We further report age-dependent cognitive decline in a mouse model 
overexpressing murine Synj1 to the levels observed in human sporadic AD, triggered through 
hippocampal hyperexcitability and defects in the spatial reproducibility of place fields. Taken 
together, our findings suggest that SYNJ1 contributes to memory deficits in the aging 
hippocampus in all forms of AD.
Graphical Abstract
INTRODUCTION
Synaptic function is under the rigorous control of phosphoinositide turnover, and 
phosphatidylinositol-4,5-bisphosphate (PtdIns[4,5]P2) is particularly important in this 
process (Di Paolo et al., 2004). The PtdIns(4,5)P2 phosphatase synaptojanin 1 (Synj1) is a 
key regulator of synaptic vesicle endocytosis and reavailability on the pre-synaptic side 
(Cremona et al., 1999; Kim et al., 2002; Mani et al., 2007; McPherson et al., 1996; 
Verstreken et al., 2003), while on the post-synaptic side, it controls the endocytosis of α-
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors (Gong and De 
Camilli, 2008).
A body of literature supports the importance of SYNJ1 in neurodegenerative disorders, 
including Alzheimer’s disease (AD). Clinically, AD is presented with memory loss and 
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spatial disorientation. Neuropathology hallmarks of this disorder include amyloid plaques, 
composed primarily of Aᵦ peptides that result from the sequential cleavage of the amyloid 
precursor protein (APP), and neurofibrillary tangles of hyperphosphorylated Tau (Querfurth 
and LaFerla, 2010). The three forms of AD—familial AD (FAD), Down syndrome-related 
AD (DS/AD), and sporadic AD (SAD)—share common clinical and neuropathology 
signatures. Although early-onset FAD is caused by mutations in the APP, PSEN1, or PSEN2 
gene (Reitz et al., 2011) and DS/AD is due to triplication of human chromosome 21 (Hsa21) 
(Antonarakis, 2017; Wiseman et al., 2015), the most potent genetic risk factor for SAD is the 
ε4 allele of the APOE gene (APOE4) (Lambert et al., 2013; Strittmatter et al., 1993).
SYNJ1 was reported to be crucial for the enlargement of early endosomes (Cossec et al., 
2012), one of the earliest cellular phenotypes associated with AD, observed before amyloid 
accumulation and cognitive decline (Cataldo et al., 2000). Enlarged endosomes are present 
in neurons of APOE4 carriers (Cataldo et al., 2000) as well as in fibroblasts and 
lymphocytes from individuals with DS and SAD (Corlier et al., 2015; Cossec et al., 2012). 
C99, the C-terminal APP fragment resulting from the activity of ᵦ-secretase, has been 
reported to be required for early endosomal enlargement (Jiang et al., 2010). Importantly 
though, overexpressing APP alone is not sufficient to alter endosomal size (Cataldo et al., 
2003), and endosomal size is unaffected in APP microduplications (Cossec et al., 2012). 
However, Synj1 overexpression alone is sufficient to produce enlarged endosomes in the 
brain of transgenic mice (Cossec et al., 2012), and SYNJ1 trisomy results in increased 
endosomal size in cell lines derived from individuals with partial or full trisomy of Hsa21 
(Cossec et al., 2012). In addition, SYNJ1 has also been linked to amyloid toxicity. 
Oligomers of Aᵦ peptides disrupt PtdIns(4,5)P2 metabolism in cultured primary cortical 
neurons, and genetically decreasing Synj1 levels protects from the inhibitory effect of Aᵦ 
oligomers on hippocampal long-term potentiation in brain slices (Berman et al., 2008).
A recent study reported that APOE4 carriers show increased levels of SYNJ1 compared with 
non-carriers (Zhu et al., 2015). SYNJ1 is encoded by SYNJ1, mapping to Hsa21 (Cremona 
et al., 2000), and is increased in individuals with DS and DS/AD (Arai et al., 2002; Martin et 
al., 2014). SYNJ1 levels are thus elevated in individuals at high risk for developing SAD and 
DS/AD, but very little is known on a potential role for synaptojanin 1 in FAD. To our 
knowledge, only indirect evidence in model systems has currently been published. 
Specifically, it has been reported that PtdIns(4,5)P2 metabolism is disrupted in cells 
expressing FAD-mutant forms of presenilin 1 (Landman et al., 2006), and earlier studies 
support that genetically decreasing Synj1 levels rescues cognitive deficits in murine models 
of FAD (McIntire et al., 2012; Zhu et al., 2013), although the mechanisms involved are still 
controversial.
The present study addresses whether SYNJ1 is associated with human FAD. It also explores 
whether elevated levels of SYNJ1 directly affect cognition in an age-dependent manner. Our 
work, combining human genetics, human autopsy brain samples, and behavior and in vivo 
electrophysiology studies in a transgenic mouse model overexpressing murine Synj1, 
Tg(Synj1) (Voronov et al., 2008), strongly supports that SYNJ1 plays a role in the function 
of place cells in the aging hippocampus, with critical implications for memory deficits in all 
three forms of AD and their possible treatment.
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RESULTS
Variants of SYNJ1 Are Associated with Memory Performance in FAD
Individuals with DS/AD (Martin et al., 2014) and APOE4 carriers (Zhu et al., 2015) show 
increased levels of SYNJ1. We thus targeted SYNJ1 as a candidate gene that may contribute 
to phenotypic variations in FAD. Specifically, we examined whether SYNJ1 was associated 
with memory performance and age of onset in early-onset FAD by testing a cohort of 
Caribbean Hispanic families with the PSEN1-G206A mutation (Table S1) (Athan et al., 
2001; Lee et al., 2015). Intriguingly, we observed a genewise association of SYNJ1 with age 
of onset of AD (p = 0.0195) and long-term recall performance (p = 0.0443) in this cohort 
(Table S2). Our subsequent SNP analysis within SYNJ1, based on whole-genome 
sequencing (WGS) data, yielded four SNPs that were significantly associated with age of 
onset (p < 0.01; Table 1). Furthermore, we observed three additional SNPs associated with 
long-term recall scores and global memory scores (p < 0.05; Table 1).
We then determined whether the observed effect was present in late-onset FAD, a form of 
the disease defined by having multiple family members affected with late-onset AD (Romas 
et al., 2002; Zhao et al., 2013), by extending our study to the EFIGA cohort (Lee et al., 
2011; Romas et al., 2002) (Table S1). Because the EFIGA dataset lacked WGS data, we 
analyzed the candidate SYNJ1 region (bp 34,004,976–34,078,985) identified from our early-
onset FAD results, using seven tagSNPs that were found to be significant from the genome-
wide association study (GWAS) dataset available for the EFIGA cohort (Figure S1 and Table 
S3). Our subsequent sliding-window haplotype analysis indicated that window 5 in a 3-mer 
analysis (bp 34,020,786–34,027,774) and window 4 in a 4-mer approach (bp 34,020,653–
34,027,774) were the primary candidates for harboring the variant(s) that contribute to age 
of onset of AD (Table 2). Furthermore, we observed that carriers of the minor haplotype 
(AGA or AAGA) were protected against AD, as their age of onset was delayed by 8–10 
years on average (Table 2). The effect of APOE4 on age at onset was not significant. Our 
findings in human cohorts thus support an association of SYNJ1 with both early-onset and 
late-onset FAD.
To determine whether the candidate SNPs we identified in early-onset FAD may affect 
SYNJ1 expression in the brain, we examined the expression quantitative trait loci (eQTL) 
data in the GTEx Portal, restricting our analysis to the tissues in the frontal cortex. In the 
frontal cortex, we found that, on the basis of 129 tissue samples, rs2833943 located at 
34,041,650 bp and rs66528773 located at 34,080,468 bp were differentially expressed (p = 
0.00788771 for each). Their m values, representing the likelihood of functional relevance, 
were 0.978 and 0.995, respectively. Interestingly, the set of AD associated SNPs that were 
identified from early-onset FAD (Table 1) was in linkage disequilibrium with the eQTL 
identified in the frontal cortex tissues in the GTEx dataset (Figure S2), suggesting that the 
identified SNPs (or adjacent SNPs) are likely to influence SYNJ1 expression.
Elevated SYNJ1 Levels Are Associated with Synaptic Deficits in DS/AD
In light of earlier reports that SYNJ1 levels are elevated in individuals at high risk for 
developing SAD (Zhu et al., 2015) and DS/AD (Martin et al., 2014), our results in human 
Miranda et al. Page 4
Cell Rep. Author manuscript; available in PMC 2018 July 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FAD cohorts strongly suggested that SYNJ1 may play a role in all three forms of AD. This 
motivated us to investigate whether elevated SYNJ1 affects cognition in an age-dependent 
manner, an AD hallmark. We hypothesized that a large increase in SYNJ1 levels, such as the 
one observed in populations at high risk for developing DS/AD (+155% compared with age-
matched disomic controls) (Martin et al., 2014), could influence synaptic integrity. To test 
this hypothesis, we used data previously collected on post-mortem brain samples of 
individuals with DS at different ages (Martin et al., 2014). We focused on the age range of 
40–52 years, when most individuals with DS develop AD. For each individual, we plotted 
the levels of SYNJ1 against the levels of synaptophysin, a pre-synaptic protein that we used 
as a direct measure of synaptic integrity (Figure 1). Indeed, synaptophysin levels have been 
extensively and consistently found to be decreased in individuals with AD and DS/AD (e.g., 
(Downes et al., 2008; Masliah et al., 1989, 1991; Reddy et al., 2005; Terry et al., 1991). We 
found that levels of SYNJ1 were inversely correlated (p = 0.0151, R2 = 0.2862) with levels 
of synaptophysin; that is, the higher the levels of SYNJ1, the more synaptic integrity was 
compromised. In contrast, no such correlation (p = 0.1784, R2 = 0.2790) was observed in 
younger individuals with DS (age range 1–39 years), whose SYNJ1 levels are only mildly 
higher (+36%) than those of disomic controls (Figure S3). Our results thus strongly suggest 
that elevated levels of SYNJ1 observed in populations at high risk for developing AD could 
directly affect synaptic structure, function, or both.
Elevated Synj1 Levels Drive Age-Dependent Hippocampal Cognitive Deficits
To dissect the effect of elevated levels of synaptojanin 1 on cognition, we used a transgenic 
mouse model overexpressing murine Synj1, Tg(Synj1) (Voronov et al., 2008). We observed 
76% more Synj1 in the brain of transgenic mice than in littermate controls (wild-type [WT]) 
(Figure 2A). This closely recapitulates the overexpression levels (+73%) described in 
APOE4 carriers with early AD (clinical dementia rating [CDR] 0.5–1) (Zhu et al., 2015) but 
is milder than the overexpression levels in individuals with DS/AD (+155% compared with 
age-matched disomic controls) (Martin et al., 2014). Indeed, we found that levels of pre-
synaptic (synaptophysin) and post-synaptic (PSD 95)proteins were not altered in the 
hippocampi of 19-month-old transgenic versus WT animals (Figure S4A), suggesting no 
gross synaptic loss, even in older animals. Tg(Synj1) mice thus appeared as a good model 
system to dissect the effect of elevated levels of Synj1 on synaptic dysfunction and cognitive 
deficits.
We focused on two hippocampus-dependent behavior tasks, as this region is critically 
affected in AD (Stoub et al., 2006), and investigated whether the performance of transgenic 
Tg(Synj1) mice in these tasks declined with age. We first used the radial arm water maze 
(RAWM) paradigm to probe working memory. At 9 months, Tg(Synj1) and WT mice 
performed similarly in the RAWM test (Figure 2B). In contrast, at 19 months, Tg(Synj1) 
mice showed a significantly higher number of errors in the RAWM compared with WT mice 
(Figure 2B). Although WT mice experienced cognitive decline with age, age-dependent 
cognitive deficits were significantly more pronounced in Tg(Synj1) than in WT littermates 
(188% of normal aging; Figure 2C). Although 19-month-old Tg(Synj1) swam slightly 
slower than age-matched WT mice, their ability to reach a visible platform remained 
unchanged (Figure S4B), ruling out any visual or motivational impairment.
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To assess whether other forms of learning were impaired in transgenic mice, we used a fear 
conditioning (FC) paradigm. Whereas contextual fear learning depends on both 
hippocampus and amygdala, cued testing only depends on the amygdala. No difference in 
contextual or cued freezing behavior was observed between Tg(Synj1) and WT mice at 9 
months (Figure 2D). However, at 19 months, Tg(Synj1) mice showed a specific decrease in 
freezing in contextual but not in cued conditioning compared with WT mice, suggesting 
hippocampal but not amygdala impairment (Figure 2E). Taken together, our behavior results 
strongly suggest that increased levels of Synj1 drive age-dependent cognitive deficits in the 
hippocampus.
Elevated Synj1 Levels Trigger Hippocampal Place Cell Dysfunction
We then pursued the functional basis underlying hippocampal cognitive deficits in older 
Tg(Synj1) animals. Specifically, we investigated whether increased Synj1 levels could alter 
hippocampal synaptic function using in vivo electrophysiological recordings in the 
hippocampus (Figure S5A). Although the firing of hippocampal inhibitory neurons was not 
affected (Figure S5B), the average and peak firing rates of hippocampal excitatory neurons 
were significantly increased in Tg(Synj1) mice (+57% and +67% increases compared with 
WT, respectively; Figure 3A). Because these recorded excitatory neurons were place cells 
(Hussaini et al., 2011) (Figure 3B), we asked whether place field properties were altered in 
transgenic animals. The average and peak field firing rates were increased in Tg(Synj1) mice 
compared with WT (Figure 3C). The mean place field size was comparable between 
transgenic animals and controls (Figure 3D). However, place field size distribution was 
broader in Tg(Synj1) mice, highlighting a higher size variability in transgenic animals 
(Figure 3D). Information content and spatial coherence were comparable between transgenic 
and control mice (Figures 3Eand 3F). More important, the stability of place fields after 18–
24hr was decreased by more than 3-fold in Tg(Synj1) mice (Figure 3G), suggesting a 
memory retention deficit.
Overall, our findings indicate that elevated levels of Synj1 trigger acute hyperexcitability as 
well as dramatic defects in the spatial reproducibility of place fields in the hippocampus of 
older Tg(Synj1) animals. Our data from mouse model systems strongly argue that the 
elevated levels of SYNJ1 observed in DS/AD and SAD could be the cause of the age-
dependent long-term memory defects observed in AD patients.
DISCUSSION
The present study addressed whether the elevated levels of SYNJ1 observed in populations 
at high risk to develop AD could be a common feature underlying age-dependent cognitive 
deficits. This study is supported by earlier reports in AD mouse models that described an 
important role for synaptojanin 1 in mechanisms of neuronal toxicity (Berman et al., 2008; 
Cossec et al., 2012) and human data that showed elevated levels of SYNJ1 in APOE4 
carriers (Zhu et al., 2015) and in individuals with DS/AD (Martin et al., 2014) and answers 
two previously unaddressed questions. Specifically, this work addresses whether SYNJ1 is 
associated with human FAD as well as whether elevated levels of Synj1 directly affect 
cognition in an age-dependent manner.
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Our targeted gene approach extended the relevance of alterations in SYNJ1 to FAD by 
showing that variants in SYNJ1 are associated with age of onset and long-term memory 
deficits in an early-onset FAD cohort of Caribbean Hispanic families with the PSEN1-
G206A founder mutation. We further showed that variants in SYNJ1 are also associated with 
age of onset in the EFIGA cohort of late-onset FAD. Our findings highlight the relevance of 
studying the impact of SYNJ1 alterations on memory performance for AD. We observed that 
in DS/AD brain samples, higher SYNJ1 levels correlated with compromised synaptic 
integrity. We then mimicked milder SYNJ1 overexpression levels, as observed in SAD, in a 
previously described transgenic mouse model (Voronov et al., 2008). Three- to 4-month-old 
mice with a mixed FVB/C57BL/6 background showed no anxiety-related behavior (Voronov 
et al., 2008). They also did not exhibit deficits in the Morris water maze paradigm but 
performed slightly worse than control animals in the reverse platform test variation of this 
paradigm (Voronov et al., 2008). For this study, the BAC was backcrossed on the C57BL/6 
background for eight generations, and we focused on older, and thus more AD-relevant, 
animals. Our RAWM and FC behavior studies showed that increased levels of Synj1 
triggered age-dependent cognitive deficits in the hippocampus of transgenic Tg(Synj1) mice. 
Our findings support that increased levels of Synj1 did not impair learning per se in older 
animals, as evident from the non-null slope in trials 1–5 and trials 6–10 in the RAWM, but 
caused a specific defect in long-term memory retention. This is particularly well illustrated 
by the very large number of errors in the first trial of day 2 (trial 6; Figure 2B) in the RAWM 
as well as by the reduced freezing behavior after 24 hr in contextual conditioning (Figure 
2E). Using in vivo recordings, we showed that this defect is due to hippocampal 
hyperexcitability and, more specifically, to a dramatic alteration in the spatial reproducibility 
of hippocampal place fields. Taken together, our data strongly argue that the elevated levels 
of SYNJ1 observed in populations at high risk to develop AD could be sufficient to trigger 
age-dependent long-term memory retention impairment, a signature trait of the cognitive 
deficits observed in AD patients.
A key finding of our study is that levels of synaptojanin 1 can regulate the properties, 
specifically the spatial reproducibility, of hippocampal place fields. Indeed, although the 
unique role of Synj1 in synaptic function has been very well described (Cremona et al., 
1999; Gong and De Camilli, 2008; Kim et al., 2002; Mani et al., 2007; Verstreken et al., 
2003), how it translates to hippocampal spatial memory encoding remained unknown. This 
is particularly important in light of the emerging role of SYNJ1 as a crucial regulator in 
neurodegenerative diseases, including AD and Parkinson’s disease. Remarkably, mutations 
in SYNJ1 have recently been reported to be associated with early-onset progressive 
parkinsonism (Kirola et al., 2016; Krebs et al., 2013; Olgiati et al., 2014; Quadri et al., 
2013). These mutations affect the role of synaptojanin 1 at the synapse and result in defects 
in clathrin uncoating (Cao et al., 2017), in autophagosome maturation (Vanhauwaert et al., 
2017), or both.
Another central finding highlights the importance of SYNJ1 in AD. Our results establish 
synaptojanin 1 as a key regulator of age-related cognitive decline and support that 
modifications of SYNJ1 levels could be a unifying feature of memory deficits observed in 
the three types of AD (familial, sporadic, and DS/AD). To our knowledge, the only other 
protein described to be involved in all three forms of AD is APP. Indeed, APP can be 
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mutated in FAD, it maps to Hsa21, and variants in the APP gene promoter region are a risk 
factor for SAD (Guyant-Maréchal et al., 2007; Lv et al., 2008).
Our findings thus strongly argue that developing specific SYNJ1 inhibitors is an attractive 
therapeutic strategy for AD. This is supported by earlier reports showing that genetically 
decreasing Synj1 levels rescues cognitive deficits in murine models of FAD (APP and 
PSEN1 mutations) (McIntire et al., 2012; Zhu et al., 2013) and SAD (ApoE4 knockins) (Zhu 
et al., 2015). If successful, this therapy would be protective against both toxic effects of 
oligomeric Aᵦ (Berman et al., 2008) and cognitive decline linked to age and could be 
extended to all three forms of AD. Importantly, SYNJ1 can serve as an ideal drug target, as 
it is a brain-specific phosphatase. That is, its activity can be targeted by small molecules 
without affecting its structural roles, with limited secondary effects on peripheral organs. 
Our findings also provide disease-relevant functional readouts, e.g., accuracy of 
hippocampal spatial encoding, to evaluate the efficacy of these future drugs.
EXPERIMENTAL PROCEDURES
Genetics and Population
Early-Onset FAD—For the genetic study of early-onset FAD, all participating subjects 
were at least 35 years of age. FAD patients, with the age at onset <65 years, met the research 
criteria of the National Institute of Neurological and Communicative Disorders and Stroke 
(NINCDS) and the AD and Related Disorders Association (ADRDA) for probable or 
possible AD (McKhann et al., 1984). We studied 305 family members from 45 Caribbean 
Hispanic families that had at least one G206A founder mutation in the PSEN1 gene 
(PSEN1-G206A), in which approximately 50% of the family members were carriers of the 
PSEN1-G206A (Athan et al., 2001; Lee et al., 2015).
To obtain WGS data on all family members while minimizing sequencing costs, we first 
selected two to four highly informative family members from each branch of the pedigree 
using the GIGI algorithm (Cheung et al., 2013) and performed WGS on the Illumina HiSeq 
2500 platform. In addition, we alsoperformed GWAS on all clinically evaluated family 
members in the pedigree. To generate WGS data for all family members, we applied 
SHAPIT2 (Delaneau et al., 2013) and IMPUTE2 (Howie et al., 2009) to impute sequence 
data into GWAS in family members who were not sequenced. To ensure high-quality 
imputation in this admixed cohort, we used in-house WGS data generated from 608 
Caribbean Hispanics from Puerto Rico and the Dominican Republic, plus the 1000 Genomes 
data (n = 2,504) as a reference panel. Standard quality control (QC) procedures were 
performed (Howie et al., 2012). To determine whether genetic variants in SYNJ1 were 
associated with variation in age at onset of AD and memory traits, specifically global 
memory, long-term recall and delayed recall, we first performed a gene-wise analysis while 
taking into account AD status, sex, PSEN1-G206A, level of education, APOE4, and 
principal components 1–3, as implemented in FamSKAT (Chen et al., 2013) for each trait. 
For the purpose of analysis, we followed the convention of survival analysis and defined age 
at onset of AD as follows: if affected, age at onset was used as the age at onset; if 
unaffected, age at last examination was used. To determine whether certain variants within 
SYNJ1 were significantly associated with the traits, we performed a SNP-wise analysis for 
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the variants in SYNJ1 while controlling for the same set of covariates as well as kinship 
coefficient to take into account non-independence among family members. Linear mixed 
modeling was performed using R (http://cran.r-project.org/web/packages/kinship2/
kinship2.pdf).
Replication in Late-Onset AD—To determine whether the observed genetic association 
between SYNJ1 and early-onset FAD was present in late-onset AD as well, we examined the 
role of SYNJ1 by evaluating the EFIGA cohort, which comprises both Caribbean Hispanic 
families with late-onset AD (Lee et al., 2011; Romas et al., 2002) and unrelated Caribbean 
Hispanics with SAD (Tosto et al., 2015) (see Table S1 for their characteristics). Genotyping 
data were obtained using multiple batches of SNP microarray platforms (see Table S3). We 
performed a sliding-window haplotype analysis using the GMMAT algorithm (Chen et al., 
2016), taking three or four tagSNPs at a time. We then compared the mean age at onset 
associated with the risk haplotype.
Recruitment, informed consent, and study procedures for the above two studies were 
approved by the institutional review boards of the Columbia University Medical Center 
(AAA R5816 for the Genetic modifier study and AAA PO477 for EFIGA).
Human Subjects, Autopsy Brain Tissue, and Western Blot
Characteristics of autopsy cases, as well as brain tissue preparation protocol and western 
blotting procedures, were previously described in full detail (Martin et al., 2014).
Mouse Models
Two different mouse models were tested: (1) Tg(Synj1) mice and (2) their C57BL/6 control 
littermates (WT). The Tg(Synj1) line was a kind gift from the Antonarakis lab. It was 
generated on the FVB background using mouse BAC RPCI-23 402J16, as described 
previously (Voronov et al., 2008). This BAC also contains two additional complete genes, 
the mouse orthologs of C21orf59 and C21orf66 (Voronov et al., 2008). The expression of 
C21orf59 is enriched in the cerebellum (https://gtexportal.org/home/gene/C21ORF59). The 
C21orf59 protein controls primary cilia motility and polarization (Austin-Tse et al., 2013; 
Jaffe et al., 2016). The expression of C21orf66, also called PAXBP1, is enriched in the 
cerebellum too (https://gtexportal.org/home/gene/PAXBP1). PAXBP1 is an adaptor protein 
linking the transcription factors PAX3 and PAX7 to the histone methylation machinery in 
muscle precursor cells (Diao et al., 2012). A variant of PAXBP1 was recently linked to 
myopathic hypotonia (Alharby et al., 2017). Contributing effects from these genes cannot be 
excluded. For this study, the BAC was backcrossed on the C57BL/6 background for eight 
generations. Genotypes were assessed using PCR. All animals were hemizygous for the 
BAC transgene. All procedures were performed following NIH guidelines in accordance 
with Institutional Animal Care and Use Committee (IACUC) protocols. Tests were 
performed on 4–14 mice for each genotype group. All experiments were performed blind 
with respect to the genotype. Behavior experiments were performed on two age groups: 9 
months (range 8–11 months) and 19 months (range 18–22 months). Because of technical 
considerations, in vivo electrophysiology recordings were performed on a larger age range 
(19–31 months), with an average age of 24 months at recording. All experiments were 
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performed on age-matched mice for each genotype group. Separate tests were performed for 
males and females. Because no sex-specific differences were found, results from both 
genders were pooled.
Statistical Analysis
Statistical calculations were performed using GraphPad Prism version 5.02. All data are 
expressed as mean ± SEM. In most cases, when comparing two samples, two-tailed 
Student’s t test was performed. When variances were not comparable, Welch’s correction 
was applied. When the distribution could not be assumed to be Gaussian, we used a non-
parametric Mann-Whitney test. When more samples were compared and Bartlett’s test 
showed that variances could be compared, we used one-way ANOVA with Dunnett’s post-
test or two-way ANOVA with the Bonferroni post-test. If variances could not be compared 
(p value in Bartlett’s test < 0.05), we used t tests. When more samples were compared and 
when the distribution could not be assumed to be Gaussian, we used the Kruskal-Wallis test. 
The chi-square test was used to compare distributions. Outliers, defined as values that were 
superior to (mean + 3 SDs) or inferior to (mean − 3 SDs) were excluded.
DATA AND SOFTWARE AVAILABILITY
The authors declare that all the data supporting the findings of this study are available within 
the article and its Supplemental Information files or are available from the corresponding 
author on request. The accession number for the WGS data obtained from members of 
families with early onset PSEN1-G206A mutation carriers reported in this paper is National 
Institute on Aging Genetics of AD Data Storage Site (NIAGADS): NG00064.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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In Brief
Miranda et al. combine human genetics, human brain samples, and behavior and 
electrophysiology in a transgenic mouse model to show that synaptojanin 1 levels 
regulate the function of place cells in the aging hippocampus. The results have 
implications for memory deficits in all types of Alzheimer’s disease.
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Highlights
• SYNJ1 variants associate with age of onset in familial Alzheimer’s disease
• SYNJ1 and synaptophysin are inversely correlated in adults with Down syndrome
• Aged mice overexpressing Synj1 exhibit cognitive decline and place field defects
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Figure 1. Elevated SYNJ1 Levels Are Associated with Synaptic Deficits in DS/AD
Western blot analysis of SYNJ1 and synaptophysin in human post-mortem brain samples 
from the mid-frontal cortex (BA46) of individuals with DS, aged 40–52 years (Martin et al., 
2014) (n = 20). The line represents the linear regression (R2 = 0.29, p = 0.015). See also 
Figure S3 for additional information.
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Figure 2. Overexpression of Synj1 Drives Hippocampal-Dependent Cognitive Deficits in an Age-
Dependent Manner
(A) Western blot analysis of Synj1 in 19-month-old WT and Tg(Synj1) mice (n = 4). 
Tubulin was used as an equal loading marker. Synj1 protein levels were 76% higher in 
Tg(Synj1) (1.76 ± 0.11) than in WT (1.00 ± 0.05) mice. ***p < 0.001 in unpaired Student’s 
t test.
(B) Performance of WT and Tg(Synj1) mice at 9 (n = 8 WT and 7 Tg[Synj1] mice) and 19 
(n = 9 mice for both genotypes) months in the radial arm water maze (RAWM). Mice were 
administered 30 trials over a 2-day period, and the number of errors was averaged over three 
trials. Two-way ANOVA revealed an interaction between genotype and trial block at 19 
months but not at 9 months. ns, p > 0.05, and **p < 0.01 for the overall effect of genotype in 
two-way ANOVA. In trial 6, ***p < 0.001 for the effect of genotype in two-way ANOVA 
with Bonferroni post-test.
(C) Age-dependent modification of RAWM performance of WT and Tg(Synj1) mice. Age-
dependent cognitive deficits were more severe in Tg(Synj1) mice (188 ± 25%, n = 9) than in 
WT mice (100 ± 20%, n = 9). *p < 0.05 in unpaired Student’s t test.
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(D and E) Freezing response in the contextual and cued FC paradigm in (D) 9-month-old 
WT (n = 10) and Tg(Synj1) (n = 9) mice and in (E) 19-month-old WT (n = 11) and 
Tg(Synj1) (n = 7) mice. *p < 0.05 in unpaired Student’s t test.
Data are represented as mean ± SEM. See also Figure S4 for additional information.
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Figure 3. Overexpression of Synj1 Results in Hippocampal Hyperexcitability and Decreased 
Place Field Stability
(A) Left: average firing rate of hippocampal excitatory (pyramidal) neurons in 24-month-old 
Tg(Synj1) mice (3.2 ± 0.2 Hz, n = 72 neurons from six animals) and controls (2.0 ± 0.2 Hz, 
n = 98 neurons from five animals). Right: peak firing rate of pyramidal neurons in Tg(Synj1) 
mice (9.3 ± 0.7 Hz) and controls (5.6 ± 0.4 Hz). ***p < 0.001 in Mann Whitney test.
(B) Representative examples of firing rate maps showing place fields obtained after WT and 
Tg(Synj1) mice explored a 50-cm-diameter cylindrical arena for 20 min. The firing rate is 
represented by a heatmap ranging from blue (no firing) to red (peak firing). White spaces 
indicate locations not visited by the animal.
(C) Left: average field firing rate in Tg(Synj1) mice (3.8 ± 0.3 Hz, n = 72 neurons) and 
controls (2.2 ± 0.2 Hz, n = 98 neurons). Right: peak field firing rate in Tg(Synj1) mice (9.2 
± 0.7 Hz) and controls (5.5 ± 0.4 Hz). ***p < 0.001 in Mann-Whitney test.
(D) Size of place fields in Tg(Synj1) and WT mice. The average size (left) of place fields 
was comparable (p > 0.05 in Mann-Whitney test) between Tg(Synj1) (1,066 ± 58 cm2, n = 
72 neurons) and WT (1,043 ± 24 cm2, n = 98 neurons) mice, although the distribution (right) 
of place field sizes was significantly different (***p < 0.001 in chi-square test).
(E) Comparable (p > 0.05, Mann-Whitney test) information content between Tg(Synj1) 
(0.29 ± 0.05 bits/spike, n = 72) and WT (0.19 ± 0.03 bits/spike, n = 98) neurons.
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(F) Similar spatial coherence (p > 0.05, Mann-Whitney test) between Tg(Synj1) (2.25 
± 0.03, n = 72) and WT (2.21 ± 0.02, n = 98) neurons.
(G) Place field stability at 18–24 hr was significantly decreased (*p < 0.05 in unpaired 
Student’s t test) in Tg(Synj1) mice (0.05 ± 0.04, n = 20 neurons) compared with controls 
(0.17 ± 0.03, n = 24 neurons).
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Table 1.
Association of SNP within SYNJ1 Gene with Age at Onset and Memory Scores in a Cohort of Caribbean 
Hispanic Families with the PSEN1-G206A Mutation
Age at Onseta Global Memoryb Long-Term Recallb Delayed Recallb
SNP Location (bp) Beta p Value Beta p Value Beta p Value Beta p Value
21:34004976 34,004,976 −0.77 0.6602 5.90 0.0397c 6.81 0.0083c 1.04 0.0504
21:34006054:G:T 34,006,054 14.91 0.0094c 9.88 0.3092 5.71 0.5150 1.45 0.4203
21:34012999 34,012,999 0.22 0.8909 6.46 0.0137c 7.14 0.0024c 1.10 0.0230c
21:34019201 34,019,201 −16.14 0.0061c 7.06 0.5553 6.84 0.5278 3.00 0.1862
21:34041167 34,041,167 −10.23 0.0010c 2.94 0.6074 1.23 0.8125 −0.21 0.8402
rs200644223:34057206:
ACGGCCGGG:A
34,057,206–34,057,214 −0.98 0.7395 −15.13 0.0004c −11.55 0.0029c −2.14 0.0066c
21:34078985 34,078,985 22.46 0.0050c −0.09 0.9939 −4.05 0.7115 2.39 0.2821
See also Figure S2 and Tables S1 and S2 for additional information.
aCovariates included AD, sex, PSEN1-G206A, education, APOE4, and principal components (PC1, PC2, and PC3). Age at onset is defined as age 
at onset for affected individuals and age at last examination for unaffected individuals (see text for details).
bCovariates included age at onset, sex, education, APOE4, and principal components (PC1, PC2, and PC3).
cp < 0.05.
Cell Rep. Author manuscript; available in PMC 2018 July 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Miranda et al. Page 23
Ta
bl
e 
2.
Sl
id
in
g-
W
in
do
w
 H
ap
lo
ty
pe
 A
na
ly
sis
 o
f S
YN
J1
 
G
en
e 
in
 L
at
e-
O
ns
et
 F
A
D
 (E
FI
GA
)
rs
11
70
27
74
rs
28
33
93
0
rs
28
33
93
1
rs
10
47
01
65
rs
17
69
45
46
rs
28
33
93
4
rs
28
33
93
5
M
od
el
 1
M
od
el
 2
H
1/
H
1
H
1/
−
−
/−
A
/G
(a
)
A
/G
A
/G
G
/A
A
/C
A
/G
G
/A
H
ap
lo
ty
pe
p 
Va
lu
eb
p 
Va
lu
ec
M
ea
n
SD
M
ea
n
SD
M
ea
n
SD
W
in
do
w
1
G
A
A
0.
11
45
0.
10
19
67
.9
10
.5
70
.7
9.
8
71
.2
9.
8
W
in
do
w
2
A
A
A
0.
20
72
0.
18
28
69
.8
10
.4
71
.1
9.
8
71
.2
9.
7
W
in
do
w
3
A
A
A
0.
07
09
0.
05
80
80
.0
1.
4
72
.4
10
.7
71
.0
9.
8
W
in
do
w
4
A
A
G
0.
07
09
0.
05
80
80
.0
1.
4
72
.4
10
.7
71
.0
9.
8
W
in
do
w
5
A
G
A
0.
04
18
d
0.
03
42
d
80
.0
1.
4
72
.5
10
.7
70
.7
9.
8
W
in
do
w
1
G
A
A
A
0.
11
84
0.
10
59
67
.9
10
.5
70
.7
9.
8
71
.2
9.
8
W
in
do
w
2
A
A
A
C
0.
34
10
0.
29
79
70
.4
10
.3
71
.0
9.
8
71
.2
9.
7
W
in
do
w
3
A
A
A
G
0.
07
14
0.
05
84
80
.0
1.
4
72
.4
10
.7
71
.0
9.
8
W
in
do
w
4
A
A
G
A
0.
03
23
d
0.
02
56
d
80
.0
1.
4
72
.4
10
.7
70
.7
9.
8
Se
e 
al
so
 F
ig
ur
e 
S1
 a
nd
 T
ab
le
s S
1 
an
d 
S3
 fo
r a
dd
iti
on
al
 in
fo
rm
at
io
n.
a A
 m
in
or
 a
lle
le
 is
 p
re
se
nt
ed
 fi
rs
t.
b C
ov
ar
ia
te
s f
or
 m
od
el
 1
: A
lz
he
im
er
’s
 d
ise
as
e,
 se
x
, 
ed
uc
at
io
n,
 A
PO
E4
,
 
pr
in
ci
pa
l c
om
po
ne
nt
s (
PC
s),
 an
d g
en
eti
c r
ela
tio
ns
hip
 m
atr
ix 
(G
RM
).
c C
ov
ar
ia
te
s f
or
 m
od
el
 2
: s
im
ila
r t
o 
m
od
el
 1
 b
u
t e
x
cl
ud
es
 A
PO
E4
.
d p
 <
 0
.0
5.
Cell Rep. Author manuscript; available in PMC 2018 July 11.
